Although Pyk2 inhibitors have demonstrated promising preclinical efficacy in various preclinical models and non-brain tumors [57,90,91], clinical trials using Pyk2/FAK inhibitors as monotherapies have shown only modest benefits in progression-free survival [92,93]. This evidence concerns the gene PTK2B and brain neoplasm.